HealthCor Management’s Sarepta Therapeutics SRPT Stock Holding History

HealthCor Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50,280	Closed	-$6.49M	–	59
2019 Q4	$6.49M	Buy	+50,280	New	+$5.07M	0.23%	52
2018 Q1	–	Sell	-1,309,960	Closed	-$72.9M	–	51
2017 Q4	$72.9M	Buy	1,309,960 +107,190	+9%	+$5.68M	2.37%	18
2017 Q3	$54.6M	Sell	1,202,770 -829,120	-41%	-$33.1M	1.83%	20
2017 Q2	$68.5M	Buy	2,031,890 +481,890	+31%	+$15.7M	2.47%	15
2017 Q1	$45.9M	Buy	+1,550,000	New	+$48M	2.1%	16
2015 Q3	–	Sell	-365,000	Closed	-$11.1M	–	55
2015 Q2	$11.1M	Sell	365,000 -97,700	-21%	-$2M	0.56%	35
2015 Q1	$6.14M	Buy	+462,700	New	+$6.17M	0.29%	56

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HealthCor Management's SRPT Position: Q1 2020 in Review

HealthCor Management sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 50,280 shares — an estimated $6.49M sold.

HealthCor Management first reported a position in SRPT in Q1 2015 and held it in 7 quarters. The position peaked at $72.9M in Q4 2017. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

HealthCor Management reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
HealthCor Management sold 50,280 Sarepta Therapeutics shares in Q1 2020, an estimated $6.49M.
HealthCor Management first reported a position in Sarepta Therapeutics in Q1 2015 and held it in 7 quarters.
HealthCor Management's Sarepta Therapeutics position peaked at $72.9M in Q4 2017.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on HealthCor Management's 13F filing for Q1 2020, filed 15 May 2020.